Key Insights

Highlights

Success Rate

79% trial completion

Published Results

13 trials with published results (10%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

10.2%

13 terminated out of 128 trials

Success Rate

79.4%

-7.1% vs benchmark

Late-Stage Pipeline

10%

13 trials in Phase 3/4

Results Transparency

26%

13 of 50 completed with results

Key Signals

13 with results79% success13 terminated

Data Visualizations

Phase Distribution

95Total
Not Applicable (31)
Early P 1 (2)
P 1 (28)
P 2 (21)
P 3 (10)
P 4 (3)

Trial Status

Completed50
Unknown33
Recruiting17
Terminated13
Active Not Recruiting8
Withdrawn3

Trial Success Rate

79.4%

Benchmark: 86.5%

Based on 50 completed trials

Clinical Trials (128)

Showing 20 of 20 trials
NCT05489237Phase 1RecruitingPrimary

First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors

NCT04084249Not ApplicableActive Not Recruiting

ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial

NCT06996483CompletedPrimary

Impact of Oral Versus Intravenous 5-FU-Based Adjuvant Regimens on Sleep Quality and Depression in Patients With Gastrointestinal Cancers

NCT07389525Early Phase 1Not Yet RecruitingPrimary

Immune Checkpoint Inhibitor (ICI)-Drug-Drug Interaction (DDI) Study

NCT07222800Phase 3Recruiting

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

NCT06663319Phase 1Recruiting

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT04919824Not ApplicableActive Not RecruitingPrimary

Monopolar Current Cutting Knife vs Bipolar RFA Knife

NCT01750619RecruitingPrimary

Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions

NCT05772546Phase 2Active Not Recruiting

Avatrombopag vs. Placebo for CIT in GI Malignancies

NCT04426669Phase 1Completed

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

NCT04907643Not ApplicableRecruiting

Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

NCT07218926Phase 3RecruitingPrimary

A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy

NCT05707286Completed

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy

NCT07319364Phase 1Recruiting

A Real-World Study of Fecal Transplants for Cancer Therapy Side Effects

NCT04592913Phase 3Active Not RecruitingPrimary

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04937647RecruitingPrimary

Evaluation of Neoplasia With Artificial Intelligence in Gastrointestinal Endoscopy

NCT01946854Not ApplicableActive Not RecruitingPrimary

Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei

NCT06885034Phase 1RecruitingPrimary

A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed

NCT06222645Not ApplicableRecruiting

PPG vs. ICG in Gastrointestinal Resections

NCT05980416Phase 1Terminated

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Scroll to load more

Research Network

Activity Timeline